Lung Cancer: Targets and Therapy

Lung Cancer: Targets and Therapy is an open access journal devoted to lung cancer research, published by Dove Medical Press.《Lung Cancer: Targets and Therapy》是一份致力于肺癌研究的开放获取期刊，由多夫医学出版社出版。

It was launched in 2010 and carries peer-reviewed work on the targets behind the disease and on the best use of treatment.该刊于 2010 年创办，刊载关于该病背后靶点与治疗最佳运用的同行评审工作。

In the 2025 edition of the journal citation report it holds an impact factor of 3.3, and it stands in the second quartile of oncology.在 2025 年版期刊引证报告中，该刊的影响因子为 3.3，在肿瘤学类目列第二区。

Scope

• The journal is international in outlook, and it takes work that bears on the prevention, diagnosis and treatment of lung cancer.该刊放眼国际，收载关系到肺癌预防、诊断与治疗的工作。

• Identification of therapeutic targets is central, and the journal carries work on the molecules a treatment might be aimed at.治疗靶点的识别是核心，该刊刊载治疗可能瞄准的分子方面的工作。

• Preventative and integrated treatment is named, and the journal admits work on how interventions are combined for a better outcome.预防性与整合治疗被点名，该刊收载干预如何组合以取得更好结果的工作。

• Epidemiology is treated as a subject, and the journal takes work on how the disease is distributed and how it is tracked.流行病学作为选题得到处理，该刊收载疾病如何分布、如何追踪的工作。

• Detection and screening are named, and the journal carries work on how a case is found early and how a programme is run.检测与筛查被点名，该刊刊载病例如何被早期发现、项目如何运行的工作。

• Cellular research is part of the remit, and the journal admits work on the biology of the tumour cell.细胞研究属于收稿范围，该刊收载肿瘤细胞生物学方面的工作。

• Biomarkers are treated, and the journal takes work on how a marker tells the type of a tumour or its course.生物标志物得到处理，该刊收载标志物如何显示肿瘤类型或病程的工作。

• Biotargets and agents with novel mechanisms of action are sought, and the journal carries work on a compound that acts in a new way.生物靶点与具新作用机制的药剂受到求取，该刊刊载以新方式起作用的化合物方面的工作。

• The optimal clinical use of existing anticancer agents is treated, and the journal asks how a drug already in hand is best employed.现有抗癌药的临床最佳运用得到处理，该刊追问手中已有的药物如何被最好地使用。

• Combination therapies are named, and the journal admits work on how two or more treatments are used together.联合治疗被点名，该刊收载两种或更多治疗如何并用的工作。

• Clinical and epidemiological studies are taken, and the journal carries work that follows patients as well as work that follows populations.临床与流行病学研究受到收载，该刊既刊载随访患者的工作，也刊载随访人群的工作。

• Basic science is admitted alongside the clinical, and the journal takes work that sets out a mechanism before it is tried in a person.基础科学同临床工作一并收载，该刊收载在人体试用之前阐明机制的工作。

• Reviews and evaluations are published, and the journal asks that a survey of a field end in a judgement.综述与评价予以发表，该刊要求对某一领域的检视以判断作结。

• Guidelines and expert opinion are taken, and the journal gives room to a reasoned statement of how a case ought to be handled.指南与专家意见受到收载，该刊为病例应如何处理的审慎陈述留出篇幅。

• Case reports and extended reports are welcomed, and the journal takes a detailed account of one patient or of a series.病例报告与详报受到欢迎，该刊收载对单一患者或一系列病例的详尽记述。

• Commentary is admitted, and the journal carries a short argument on how a finding ought to be read.评论受到收载，该刊刊载关于某项发现应如何解读的短论。

• Meta-analyses are no longer considered, and the journal makes that limit plain in its aims.荟萃分析不再受理，该刊在其宗旨中把这一界限写得明白。

History

• The journal was launched in 2010 by Dove Medical Press, and it has appeared as an electronic title from its first volume.该刊于 2010 年由多夫医学出版社创办，自首卷起便以电子刊物的形式出现。

• Only one number is in use for the title, and the journal is published online rather than in print.该刊只使用一个刊号，以在线而非印刷形式出版。

• A volume is published for each year, and the series had reached volume 17 by 2026.该刊每年出版一卷，到 2026 年已出至第 17 卷。

• Dove Medical Press began in New Zealand, and it was later taken into the Taylor & Francis group, the academic arm of Informa.多夫医学出版社起于新西兰，后并入泰勒-弗朗西斯集团，即英富曼旗下的学术部门。

• The house is now registered in London, and the journal is issued under the Dove imprint from a British address.该社现注册于伦敦，该刊以多夫的名义自一处英国地址发行。

• Access was open from the start, and every article is free to read from the moment it appears.该刊自始即开放获取，每篇文章自出现那一刻起即可免费阅读。

• A publication charge is levied on an accepted paper, and the journal publishes the amount and the waiver scheme on its own pages.被录用的论文须缴纳出版费用，该刊在自身页面上公布金额与减免方案。

• Articles are published continuously rather than held for an issue, so that a paper appears once it has been accepted.论文连续发表而不留待某一期，一旦被录用即行出现。

• The journal sits in a family of sister titles that share its name, among them Breast Cancer: Targets and Therapy and OncoTargets and Therapy.该刊处在一个同名姊妹刊的家族之中，其中有《Breast Cancer: Targets and Therapy》与《OncoTargets and Therapy》。

• The impact figure has moved with the field, standing at 5.1 for 2023 and reaching 3.3 in the 2025 edition.影响因子随领域而波动，2023 年为 5.1，2025 年版为 3.3。

• The journal is indexed in the emerging sources citation index, and it is carried in PubMed and in PubMed Central.该刊被新兴资源引文索引收录，并被 PubMed 与 PubMed Central 收录。

• It is also listed in Scopus and in the directory of open access journals, and its content is preserved in the usual archives.该刊亦被 Scopus 与开放获取期刊目录收录，其内容保存在惯常的档案之中。

• Collections of papers are assembled around themes, and the journal gathers work on subjects such as biomarkers that guide treatment.该刊围绕主题编成论文合集，汇集诸如指导治疗的生物标志物一类题目的工作。

Editors

• Sai-Hong Ignatius Ou of the University of California, Irvine is editor-in-chief, and he works in the division of hematology and oncology.加州大学欧文分校的（Sai-Hong Ignatius Ou）担任主编，工作于血液学与肿瘤学分部。

• His own field is the treatment of lung cancer, and he has written on targeted agents for the disease.其本人领域为肺癌的治疗，曾就针对该病的靶向药物撰文。

• The journal says it holds a rigorous review, and it reports the classes of paper it takes alongside the length each should follow.该刊称其评审严谨，并列明所收稿件的类别以及各类别应遵循的篇幅。

• Each paper is sent to independent referees, and the journal names its peer reviewers on a page of its own.每篇论文送交独立审稿人，该刊在自有页面上列出其同行评审人。

• Authors must declare any competing interest, and the journal states its ethical requirements in full.作者必须声明任何利益冲突，该刊完整说明其伦理要求。

• An article processing charge applies to a paper that is taken, and the journal gives the figure before submission.被录用的论文须缴纳文章处理费，该刊在投稿之前给出金额。

• A waiver scheme is offered to authors from certain countries, and the journal points to the publisher's scheme.该刊向某些国家的作者提供费用减免，并指明出版方的相关方案。

• The editorial office handles manuscripts through the publisher's system, and an enquiry may be made before a paper is written.编辑部通过出版方的系统处理稿件，在动笔之前可先行询问。

• Authors keep the copyright of their work, and every article is released under a licence that allows reuse with attribution.作者保留其作品的著作权，每篇文章以允许署名再用的许可发布。

• The journal asks that a study involving patients meet the usual standards, and that consent be recorded where it is required.该刊要求涉及患者的研究达到惯常标准，并在需要之处记录知情同意。

• Where a claim rests on a biomarker, the journal asks that the assay behind it be described in full so that another laboratory can repeat it.论断若依赖某项生物标志物，该刊要求完整描述其背后的检测，使另一实验室可以重复。

• Commentaries are kept short, and the journal asks that an opinion be tied to evidence rather than set loose from it.评论保持简短，该刊要求意见系于证据，而不是与证据脱开。

• The journal is read by clinicians and by medical oncologists, by researchers and by epidemiologists, and it writes for all of them.该刊的读者既有临床医生与肿瘤内科医生，也有研究人员与流行病学家，它为这几类人写作。

• A study that links a molecular finding to a patient outcome is given room, and the journal asks what the link means for care.把分子发现与患者结局相连的研究有篇幅可用，该刊追问这一联系对照护意味着什么。

• Studies that report a negative result are taken, since a target that proves unworkable is worth recording.报告阴性结果的研究也在收载之列，因为被证明行不通的靶点同样值得记录。

• Work on the tumour microenvironment appears among the subjects, and the journal carries papers on how the surroundings of a tumour shape its growth.肿瘤微环境方面的工作列于选题之中，该刊刊载肿瘤周边环境如何塑造其生长的论文。

• The journal keeps its reviews distinct from its original reports, and a reader can tell from the rubric which is which.该刊把综述与原始报告区分开来，读者可从栏目看出何者为何者。